Floatz Rating
B61/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06690281CT.gov A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | — | Withdrawn | — | — | — |
NCT06885697CT.gov Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | — | Recruiting | — | — | — |
NCT06782932CT.gov Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer | — | Recruiting | — | — | — |
NCT07066995CT.gov Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer | — | Recruiting | — | — | — |
NCT06898385CT.gov A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation | — | Recruiting | — | — | — |
NCT05093231CT.gov Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | — | Recruiting | — | — | — |
NCT06821048CT.gov Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors | — | Recruiting | — | — | — |
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06478225CT.gov Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer | — | Recruiting | — | — | — |
NCT06378047CT.gov Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
Show 63 more trialsShow fewer
NCT05872867CT.gov Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | — | Unknown | — | — | — |
NCT06196658CT.gov Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | — | Not Yet Recruiting | — | — | — |
NCT05922930CT.gov Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05945823CT.gov Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05462496CT.gov Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05605197CT.gov U87 CART in Treatment of Advanced Solid Tumor | — | Unknown | — | — | — |
NCT05014776CT.gov Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT05451849CT.gov A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05070247CT.gov A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT05052723CT.gov Cabozantinib and Pembrolizumab in Metastatic Pancreas | — | Completed | — | — | — |
NCT04146298CT.gov Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | — | Recruiting | — | — | — |
NCT05415475CT.gov Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | — | Unknown | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04660929CT.gov CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | — | Unknown | — | — | — |
NCT04390399CT.gov Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04447092CT.gov Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | — | Unknown | — | — | — |
NCT04426669CT.gov A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | — | Completed | — | — | — |
NCT04348643CT.gov Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | — | Unknown | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03935893CT.gov Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | — | Active Not Recruiting | — | — | — |
NCT03948763CT.gov A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | — | Terminated | — | — | — |
NCT03891979CT.gov Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | — | Withdrawn | — | — | — |
NCT03745326CT.gov Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | — | Terminated | — | — | — |
NCT03960060CT.gov A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors | — | Terminated | — | — | — |
NCT03634332CT.gov Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | — | Unknown | — | — | — |
NCT03797326CT.gov Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | — | Completed | — | — | — |
NCT03153410CT.gov Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | — | Completed | — | — | — |
NCT03586869CT.gov QUILT-3.080: NANT Pancreatic Cancer Vaccine | — | Terminated | — | — | — |
NCT03638193CT.gov Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | — | Unknown | — | — | — |
NCT03161379CT.gov GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | — | Completed | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03387098CT.gov QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | — | Terminated | — | — | — |
NCT03331562CT.gov A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | — | Completed | — | — | — |
NCT03190265CT.gov Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer | — | Completed | — | — | — |
NCT03329248CT.gov QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | — | Terminated | — | — | — |
NCT03190941CT.gov Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | — | Recruiting | — | — | — |
NCT03136406CT.gov QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | — | Terminated | — | — | — |
NCT02758587CT.gov Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | — | Unknown | — | — | — |
NCT03267173CT.gov Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | — | Unknown | — | — | — |
NCT02830724CT.gov Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | — | Recruiting | — | — | — |
NCT02648282CT.gov Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT02451982CT.gov Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | — | Active Not Recruiting | — | — | — |
NCT02546531CT.gov Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | — | Completed | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02465983CT.gov Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | — | Terminated | — | — | — |
NCT02305186CT.gov Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | — | Unknown | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT01595321CT.gov Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas | — | Completed | — | — | — |
NCT01583686CT.gov CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | — | Terminated | — | — | — |
NCT01459614CT.gov Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01362790CT.gov SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | — | Completed | — | — | — |
NCT01056601CT.gov Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | — | Terminated | — | — | — |
NCT01088789CT.gov Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer | — | Active Not Recruiting | — | — | — |
NCT00727441CT.gov Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT00553683CT.gov Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | — | Unknown | — | — | — |
NCT01212887CT.gov Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | — | Terminated | — | — | — |
NCT00305760CT.gov Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00002773CT.gov Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT00019084CT.gov Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00002475CT.gov Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | National Cancer Institute (NCI) | Approved | B · 61 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →